Loading…
Provider of physician staffing and services for neonatal, maternal-fetal and pediatric care in hospitals nationwide.
Provider of physician staffing and services for neonatal, maternal-fetal and pediatric care in hospitals nationwide.
Bills insurers and Medicaid for the care its doctors give, and receives supplemental payments from hospitals when billings alone do not cover staffing costs. A large share of neonatal patients are on Medicaid, so state rates matter. Formerly Mednax, it sold its radiology and anesthesia units in 2020 to focus on babies and pregnancies.
In one line: A hospital-based neonatal/pediatric physician staffing company.
Moat: narrow (scale, customer qualification). Large network of specialized neonatal/maternal-fetal physicians embedded in hospital contracts nationwide.
Headquarters: Sunrise, Florida · Founded: 1979 · Employees: 6,575
Size Pediatrix Medical (MD) is a United States Health Care company (Medical/Nursing Services) with a market value of $2.44B, the 1668th largest of 3,117 United States companies the cockpit tracks. Shares closed at $31.29 on 6 Nov 2026.
Performance Over six months the shares gained 33.1%, against +25.4% for the median peer and -1.1% for the United States market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue grew 1.9% over the last twelve months (peer median +6.1%); the operating margin is 12.2% (peer median 8.0%).
Valuation It trades at 12.9× forward earnings against a peer median of 46.0× (cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -6 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.7 points above its cost of capital (7.5% WACC).
Credit Pediatrix Medical has 1 bond outstanding ($400M), rated BB by the agencies and trading like BBB- at a weighted spread of 136 bp.
Short interest Short interest is 5.4% of the free float (15 Oct 2026).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.96B | $1.91B | $2.01B | $1.99B | $1.97B |
| Revenue growth | — | -5% | +1% | +1% | — |
| Gross profit | $488M | $472M | $422M | $385M | $431M |
| EBITDA | $262M | $253M | $216M | $194M | $236M |
| Net income | $150M | $165M | -$99.1M | -$60.4M | $66.3M |
| Free cash flow | $210M | $253M | $185M | $104M | $137M |
| Capital expenditure | $17.3M | $18.5M | $22.0M | $33.3M | $29.7M |
| Total debt | $612M | $635M | $662M | $702M | $717M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +19.2% | +8.4% | 4th highest of 21 |
| 6-month return | +33.1% | +25.4% | 8th highest of 20 |
| Distance from 52-week high | -7.3% | -15.2% | 6th highest of 21 |
| Revenue growth (TTM) | +1.9% | +6.1% | 9th lowest of 21 |
| Operating margin | 12.2% | 8.0% | 4th highest of 21 |
| Forward P/E | 12.9× | 46.0× | cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -4.5% | 15.0% | 2nd least demanding of 16 |
| Growth delivered (Del g) | +2.0% | +10.2% | 4th lowest of 16 |
| Hurdle (Req g minus delivered) | -6.5 pp | +7.0 pp | 3rd least demanding of 16 |
| ROIC minus cost of capital | +10.7 pp | -1.1 pp | 3rd highest of 20 |
| EV / EBITDA | 10.1× | 13.2× | 3rd cheapest of 12 |
| Net debt / EBITDA | 0.7× | 1.0× | 7th least indebted of 15 |
| Bond spread | 136 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pediatrix Medical MD | United States | $2.44B | +33% | +2% | 12% | 12.9× | -4.5% | +2.0% |
| Addus HomeCare ADUS | United States | $2.32B | +25% | +12% | 11% | 16.6× | 4.9% | +13.2% |
| AddLife ALIF-B.ST | Sweden | $2.29B | +25% | +2% | 8% | 40.5× | 21.6% | +14.6% |
| NeoGenomics NEO | United States | $2.18B | +88% | +11% | -6% | 58.9× | n/a | n/a |
| Aveanna Healthcare AVAH | United States | $2.89B | +97% | +20% | 11% | 15.4× | 13.4% | +10.2% |
| Meinian Onehealth Healthcare 002044.SZ | China | $2.89B | -9% | -4% | 9% | 55.1× | 5.8% | +5.7% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.99B | +5% | -3% | 7% | 31.7× | 6.7% | -6.1% |
| Dian Diagnostics 300244.SZ | China | $1.97B | +11% | -5% | 9% | 25.2× | 2.4% | -1.1% |
| Emeis EMEIS.PA | France | $1.94B | -30% | +4% | 3% | n/a | 21.3% | +8.5% |
| agilon health AGL | United States | $1.90B | +109% | 0% | -4% | 67.5× | n/a | n/a |
| Fameglow 3774.HK | Hong Kong | $3.19B | n/a | +36% | 11% | n/a | 48.8% | +48.4% |
| GeneDx WGS | United States | $1.86B | +53% | +25% | -12% | 98.7× | n/a | n/a |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 89.1× | 41.9% | +26.9% |
| Acadia Healthcare ACHC | United States | $3.44B | +47% | +4% | 10% | 18.7× | n/a | n/a |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 103.7× | 56.0% | +8.9% |
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | n/a | n/a | n/a |
| Dr. Lal PathLabs LALPATHLAB.NS | India | $3.50B | +26% | +17% | 24% | 51.5× | 32.2% | +11.8% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 40.1× | 15.0% | -5.1% |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 15.8× | 1.7% | +7.7% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 64.3× | 39.3% | +16.7% |
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | n/a | -5.2% | +18.3% |
Pediatrix Medical has 1 bond outstanding with $400M face value. The agencies rate it BB; its bonds trade like BBB-. Weighted yield 6.07%, a spread of 136 bp over government bonds.